BEIJING, CHINA — September 2026 — As global healthcare experts convene at the WHO Academy in Lyon, France, for the official World Health Organization (WHO) Consultation on the Composition of Influenza Virus Vaccines for Use in the 2027 Southern Hemisphere Influenza Season ^{[ 1],} the critical need for robust respiratory protection has taken center stage. With infectious diseases and seasonal zoonotic viral variants constantly mutating, public health organizations and global B2B procurement managers are actively seeking advanced, high-compliance physical defense barriers to shield frontline workers and communities. 

In direct response to these evolving global health priorities monitored by the WHO Global Influenza Surveillance and Response System (GISRS) ^{[ 1]}, Qinhuangdao Taizhi Medical Technology Co., Ltd. (Taizhi Medical), a leading ISO13485-certified medical protection manufacturer, has officially announced the global launch of its latest Certified 3-Ply Medical Surgical Masks. Engineered to provide premium clinical-grade barrier defense and uncompromised structural reliability, this next-generation PPE lineup arrives just ahead of the highly anticipated 94th China International Medical Equipment Fair (CMEF 2026) in Beijing. 

Advanced Filtration Meets Clinical Compliance

Designed to withstand high-risk medical and industrial environments, Taizhi Medical’s upgraded 3-ply protective face masks deliver an exceptional Bacterial Filtration Efficiency (BFE) of ≥ 95% and comply with strict fluid-resistance standards (EN14683 Type IIR, ASTM F2100). Built with a specialized high-density middle layer of premium melt-blown fabric combined with hypoallergenic non-woven inner and outer layers, the masks establish a superior physical protective barrier against microscopic droplets, airborne pathogens, blood, and harmful bodily fluids.

To guarantee absolute safety straight out of the box, every single mask  is individually wrapped, a crucial engineering design feature that completely prevents secondary contamination, extends shelf life, and ensures maximum portability for hospital staff, corporate offices, and emergency stockpiles alike.

Optimized Supply Chain Advantage for Healthcare

Wholesalers While clinical compliance remains paramount, Taizhi Medical recognizes that global procurement managers require reliable, scalable manufacturing partners to combat market price volatility. By optimizing internal polymer sourcing and utilizing highly automated production lines, Taizhi Medical delivers an uncompromising balance of strict quality control and competitive wholesale pricing.

This structural manufacturing capacity allows international hospital networks, regional distributors, and medical wholesalers to secure high-performance safety consumables with low defect rates. For global PPE suppliers, partnering directly with an ISO13485 source plant guarantees full traceability, robust raw material verification, and stable contract manufacturing capabilities.

Securing Global Supply Chains for the 2026/2027 Surge

"As the World Health Organization evaluates global surveillance data alongside the Food and Agriculture Organization (FAO) and the World Organisation for Animal Health (WOAH) to update pharmaceutical vaccines ^[1], physical defense remains the first line of protection," stated the International Business Director at Taizhi Medical. "Our facility operates under strict ISO13485 quality management systems. We provide stable contract manufacturing (OEM/ODM), flexible private labeling options, and compliant cross-border logistics to secure global supply chains ahead of the seasonal winter respiratory surge."

Meet CCW at The 94th CMEF 2026 in Beijing

International buyers, sourcing managers, and regional distributors looking to lock in high-quality PPE inventory are invited to meet the CCW executive team in person at The 94th CMEF, taking place from October 21–24, 2026, at the Capital International Exhibition & Convention Center in Beijing, China.

Exhibitor Name: Qinhuangdao Taizhi Medical Technology Co., Ltd. (CCW)

Booth Location: 📍 B3 ZB18 📍

Complimentary Premium Sample Kits containing the latest high-filtration surgical series will be available at the booth for quality evaluation, material inspection, and structural fluid-resistance testing. 

Reference:  【1】World Health Organization (WHO). (2026). "WHO Consultation on the composition of influenza virus vaccines for use in the 2027 southern hemisphere influenza season." WHO Global Influenza Surveillance and Response System (GISRS), Geneva. Available at: https://who.int